Related Experiment Videos
[Blood banks]
1Dirección General, Centro Nacional de Transfusión Sanguínea, Ave. Otón de Mendizábal No. 195, Col. Zacatenco, Deleg. Gustavo A. Madero, 07360 México, D.F. amarin@mailssa.gob.mx
Abstract:
Viral hepatitis is still one of the most common and severe complications of blood transfusions, with a high mortality rate. The incidence of viral hepatitis after blood transfusions has gone down, but it hasn't disappeared. In Mexico, the estimated risk of infection with HCV is 1 for every 103,000 units administered. The routes of transmission include infected whole blood (IgG), anti-D immunoglobulin and factor VIII. Mexico now has official regulations for blood transfusion. These laws gave place to a reduction of near 57% in the prevalence of infection among donors. The national prevalence of HCV in 2001 was estimated at 0.01 percent. Several tests, like PCR and core HCV antigen detection to determine AcHC, are being applied to guarantee the safety of national blood products.
Insights
Viral hepatitis remains a serious risk after blood transfusions, though incidence has decreased. Mexico
Area of Science:
- Transfusion Medicine
- Hepatology
- Infectious Diseases
Background:
- Viral hepatitis is a significant complication of blood transfusions, posing a high mortality risk.
- Despite reductions, viral hepatitis transmission via transfusion persists, with an estimated Hepatitis C Virus (HCV) risk of 1 in 103,000 units in Mexico.
- Transmission routes include infected blood products like whole blood (IgG), anti-D immunoglobulin, and factor VIII.
Purpose of the Study:
- To assess the impact of new regulations on blood transfusion safety in Mexico.
- To evaluate the current prevalence of Hepatitis C Virus (HCV) infection in blood donors.
- To highlight the testing strategies employed to ensure blood product safety.
Main Methods:
- Analysis of national blood transfusion regulations and their effect on donor infection rates.
- Estimation of Hepatitis C Virus (HCV) prevalence in the Mexican donor population.
- Review of diagnostic tests, including Polymerase Chain Reaction (PCR) and core HCV antigen detection for Acquired Hepatitis C (AcHC).
Main Results:
- New blood transfusion regulations in Mexico led to a 57% reduction in infection prevalence among donors.
- The national prevalence of HCV in 2001 was estimated at 0.01%.
- Advanced diagnostic tests are being implemented to enhance blood product safety.
Conclusions:
- Official regulations have significantly improved blood transfusion safety in Mexico.
- Ongoing implementation of sensitive testing methods like PCR is crucial for continued risk reduction.
- Vigilance and advanced screening are essential to minimize viral hepatitis transmission through blood transfusions.